ARCT-021
{{short description|Vaccine candidate against COVID-19}}
{{Use dmy dates|date=January 2021}}
{{about|the American vaccine|other uses|Arcturus COVID-19 vaccine (disambiguation){{!}}Arcturus COVID-19 vaccine}}
{{Infobox drug
| Verifiedfields =
| verifiedrevid =
| drug_name =
| INN =
| type = vaccine
| image =
| alt =
| caption =
| target = SARS-CoV-2
| vaccine_type = sa-mRNA
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| licence_EU =
| licence_US =
| pregnancy_AU =
| pregnancy_category =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_UK =
| legal_US =
| legal_UN =
| legal_NZ =
| legal_status =
| routes_of_administration = Intramuscular
| CAS_number = 2541451-24-3
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| PubChem =
| DrugBank =
| synonyms = LUNAR-COV19
}}
{{COVID-19 pandemic sidebar}}
ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.
Medical uses
It requires the intramuscular injection with a single dose.{{cite news |title=Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data |url=https://www.businesswire.com/news/home/20210510005846/en/Arcturus-Therapeutics-Announces-First-Quarter-2021-Company-Overview-and-Financial-Results-and-Provides-New-Clinical-Data |access-date=9 September 2021 |publisher=Businesswire |date=10 May 2021}}
Pharmacology
ARCT-021 is an self-amplifying mRNA vaccine.{{cite journal |vauthors=Low JG, de Alwis R, Chen S, Kalimuddin S, Leong YS, Mah TK, Yuen N, Tan HC, Zhang SL, Sim JX, Chan YF, Syenina A, Yee JX, Ong EZ, Sekulovich R, Sullivan BB, Lindert K, Sullivan SM, Chivukula P, Hughes SG, Ooi EE |title=A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine |journal=npj Vaccines |volume=7 |issue=1 |pages=161 |date=December 2022 |pmid=36513697 |pmc=9745278 |doi=10.1038/s41541-022-00590-x}}{{cite news |title=Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study |url=https://www.globenewswire.com/news-release/2020/08/11/2076339/0/en/Arcturus-Therapeutics-Announces-that-it-has-Initiated-Dosing-of-its-COVID-19-STARR-mRNA-Vaccine-Candidate-LUNAR-COV19-ARCT-021-in-a-Phase-1-2-study.html |publisher=Globe Newswire |date=11 August 2020}}
History
Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine.{{cite news | vauthors = Teo J | date = 15 April 2020 |title= Coronavirus: Clinical trials for Singapore's vaccine project could start in August |url=https://www.straitstimes.com/singapore/health/clinical-trials-for-singapores-vaccine-project-could-start-in-august |website=The Straits Times |access-date=27 April 2020}} The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.{{cite news | vauthors = Stanton D | date = 6 May 2020 |title=With Arcturus, Catalent bags another COVID project |work=Bioprocess Insider |url=https://bioprocessintl.com/bioprocess-insider/facilities-capacity/with-arcturus-mrna-project-catalent-bags-another-covid-vaccine-deal/|language=en-US|access-date=2020-05-08}}
= Clinical trials =
LUNAR-COV19 clinical trials in humans began in July 2020.{{ClinicalTrialsGov|NCT04480957|Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects}} On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.{{cite news |title=Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the |url=https://www.bloomberg.com/press-releases/2021-01-04/arcturus-therapeutics-receives-fda-allowance-to-proceed-with-phase-2-study-of-arct-021-lunar-cov19-vaccine-candidate-in-the |access-date=January 17, 2021 |publisher=Bloomberg |date=January 4, 2021}}
Economics
Arcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR-COV19.{{cite news | vauthors = Anwar N |title=Singapore's co-developed vaccine candidate is in 'good shape' for delivery in 2021 |url=https://www.cnbc.com/2020/11/27/singapore-arcturus-coronavirus-vaccine-candidate-on-track-for-2021-delivery.html |access-date=March 18, 2021 |publisher=CNBC |date=November 26, 2020}}{{cite news | vauthors = Cheok M, Mookerjee I |title= Singapore Will Get First Claim to Any Successful Arcturus Vaccine |url=https://www.bloomberg.com/news/articles/2020-08-04/singapore-to-get-first-claim-to-any-successful-arcturus-vaccine |access-date=March 18, 2021 |publisher=Bloomberg |date=August 5, 2020}}
References
{{reflist}}
External links
{{scholia|Q98713328}}
{{Vaccines}}
{{COVID-19 pandemic}}
{{Portal bar | Medicine | Viruses | COVID-19}}
Category:Clinical trials related to COVID-19
Category:American COVID-19 vaccines
Category:Singaporean COVID-19 vaccines
{{COVID19-vaccine-stub}}
{{vaccine-stub}}